Related Experiment Video
Updated: May 18, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
Published on: March 18, 2020
Gene therapy for primary immunodeficiencies: Part 1
Marina Cavazzana-Calvo1, Alain Fischer, Salima Hacein-Bey-Abina
1U768 INSERM, Paris, France. m.cavazzana@nck.aphp.fr
Abstract:
Over 60 patients affected by SCID due to IL2RG deficiency (SCID-X1) or adenosine deaminase (ADA)-SCID have received hematopoietic stem cell gene therapy in the past 15 years using gammaretroviral vectors, resulting in immune reconstitution and clinical benefit in the majority of them. However, the occurrence of insertional oncogenesis in the SCID-X1 trials has led to the development of new clinical trials based on integrating vectors with improved safety design as well as investigation on new technologies for highly efficient gene targeting and site-specific gene editing. Here we will present the experience and perspectives of gene therapy for SCID-X1 and ADA-SCID and discuss the pros and cons of gene therapy in comparison to allogeneic transplantation.
More Related Videos
Related Concept Videos
Gene Therapy
Gene Therapy
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Microorganisms in Medicine and Therapeutics
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Tumor Immunotherapy

